NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors.

about

YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting.WWC3 inhibits epithelial-mesenchymal transition of lung cancer by activating Hippo-YAP signaling.

P2860

Q53686708-517A49BD-6927-4C03-B0C8-3C694B3926CD Q55393865-159F7357-00CB-4384-A2FE-3B5217B60F12

P2860

NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors.

Item

http://www.wikidata.org/entity/Q41010553

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

NSCLC depend upon YAP expressi ...... resistance to EGFR inhibitors.

@en

type

Item

label

NSCLC depend upon YAP expressi ...... resistance to EGFR inhibitors.

@en

prefLabel

NSCLC depend upon YAP expressi ...... resistance to EGFR inhibitors.

@en

P1476

NSCLC depend upon YAP expressi ...... resistance to EGFR inhibitors.

@en

P2093

Ann Rita Halvorsen

http://www.w3.org/2001/XMLSchema#string

Lilach Kleinberg

http://www.w3.org/2001/XMLSchema#string

P2860

TEAD mediates YAP-dependent gene induction and growth control

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components.

Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition.

AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma.

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.

P304

497-504

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/GENESANDCANCER.136

http://www.w3.org/2001/XMLSchema#string

P433

3-4

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Åslaug Helland

Odd Terje Brustugun

Marc McGowan

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28680534

http://www.w3.org/2001/XMLSchema#string

P932

5489647

http://www.w3.org/2001/XMLSchema#string

NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors.

about

P2860

P2860

NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932